TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have earned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $9.00.

Several analysts recently commented on HURA shares. Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Sunday. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Tuesday, April 21st. Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a report on Wednesday, April 15th. They set a “buy” rating for the company. Citizens Jmp began coverage on shares of TuHURA Biosciences in a report on Monday, April 27th. They set a “market outperform” rating and a $9.00 price target for the company. Finally, Citigroup began coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued an “outperform” rating for the company.

TuHURA Biosciences Stock Performance

HURA stock opened at $2.12 on Thursday. The stock has a market cap of $135.00 million, a P/E ratio of -3.48 and a beta of 0.01. The firm has a 50 day simple moving average of $2.27 and a 200 day simple moving average of $1.60. TuHURA Biosciences has a 52 week low of $0.41 and a 52 week high of $3.90.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Sell-side analysts predict that TuHURA Biosciences will post -0.56 EPS for the current year.

Institutional Trading of TuHURA Biosciences

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in TuHURA Biosciences in the third quarter valued at approximately $26,000. JPMorgan Chase & Co. acquired a new stake in TuHURA Biosciences in the second quarter valued at approximately $27,000. Wells Fargo & Company MN lifted its stake in TuHURA Biosciences by 109.0% in the fourth quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock valued at $29,000 after acquiring an additional 19,931 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in TuHURA Biosciences in the fourth quarter valued at approximately $30,000. Finally, Invesco Ltd. acquired a new stake in TuHURA Biosciences in the second quarter valued at approximately $30,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.